|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue from collaboration agreements | |||||
| Research and development expenses | |||||
| General and administrative expenses | |||||
| Other income | |||||
| Operating result | |||||
| Financial expenses | |||||
| Change in fair value of liabilities for warrants | |||||
| Other financial income | |||||
| Other financial expenses | |||||
| Financial result | |||||
| Profit/(loss) before taxes | |||||
| Taxes on income | |||||
| Net profit/(loss) | |||||
| Weighted average shares outstanding—basic and diluted | |||||
| Non-controlling interest | |||||
| Net profit/(loss) per share: | |||||
| Basic | |||||
| Diluted | |||||
Loading...